- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02823886
Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers (RIFIFI)
Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers of Inflammation
An intense inflammatory reaction is triggered by the ischemic injury during myocardial infarction. The inflammatory processes involved are complex and haven't been explored in detail in human patients. This inflammatory response can increase myocardial damage following reperfusion, leading to adverse remodeling and adverse events (heart failure, sudden cardiac death).
Cardiac MRI can assess the size of myocardial infarction and many other parameters associated with myocardial injury: edema, hemorrhage, micro-vascular obstruction.
(However the association between biomarkers of inflammation and these imaging parameters is not known).
There is very little data correlating imaging markers of myocardial injury to the biokinetics of inflammation biomarkers.
In this study, the aim is to assess the relationship between the kinetics of specific inflammatory biomarkers (interleukin-1beta, interleukin 6, interleukin 17, Tumor Necrosis Factor (TNF)-alpha, C reactive protein (CRP), soluble toll-like receptor-2 (ST2), neutrophils) and imaging markers of injury measured by cardiac MRI at the acute phase in 20 acute mycardial infarction (AMI) patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- Hospices Civils de Lyon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients, aged over 18, without any legal protection measure,
- Having a health coverage,
- Presenting within 12 hours of the onset of chest pain,
- Who have ST segment elevation ≥0.2 millivolt (mV) in two contiguous leads,
- For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).
- he culprit coronary artery has to be the left anterior descending (LAD) or the right coronary (RC)
- The LAD or RC artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
- Preliminary oral informed consent followed by signed informed consent as soon as possible
- Final TIMI ≥ 2
Exclusion Criteria:
- Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
- Patients with cardiogenic shock
- Patient in Cardiac arrest
- History of Myocardial Infarction
- Contre-indication to MRI : claustrophobia, pacemaker or cardiac defibrillator , eye metal body allergy to gadolinium
- Patient with Atrial Fibrillation.
- Patients with loss of consciousness or (Glasgow <14)
- known renal insufficiency (either known creatinin clearance < 30 ml/min/1.73m² or current medical care for severe renal insufficiency)
- Patients with any disorder associated with immunological dysfunction
- Adult with legal protection measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STEMI patients
|
The infarct size measured on MRI at 7 days.
Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship between interleukin-1beta serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Relationship between interleukin 6 serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Relationship between interleukin 17 serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Relationship between TNF-alpha serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Relationship between CRP serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Relationship between ST2 serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Relationship between polymorphonuclear neutrophil serum level and infarct size
Time Frame: Day 7
|
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
|
Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship between H24 peak or area under curve interleukin-1beta serum level and the size of no reflow
Time Frame: Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
Relationship between H24 peak or area under curve interleukin 6 serum level and the size of no reflow
Time Frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
Relationship between H24 peak or area under curve interleukin 17 serum level and the size of no reflow
Time Frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
Relationship between H24 peak or area under curve TNF-alpha serum level and the size of no reflow
Time Frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
and concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
Relationship between H24 peak or area under curve CRP serum level and the size of no reflow
Time Frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
and concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
Relationship between H24 peak or area under curve polymorphonuclear neutrophil serum level and the size of no reflow
Time Frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
and concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
Relationship between H24 peak or area under curve ST2 serum level and the size of no reflow
Time Frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
|
Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
|
relationship between the H24 peak values of serum level for interleukin 1 beta and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for interleukin 6 and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for interleukin 17 and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for TNF-alpha and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for CRP and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for ST2 and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for polynuclear neutrophil and the cardiovascular events
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
|
|
relationship between the H24 peak values of serum level for interleukin-1beta and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between the H24 peak values of serum level for interleukin 6 and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between the H24 peak values of serum level for interleukin 17 and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between the H24 peak values of serum level for TNF-alpha and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between the H24 peak values of serum level for CRP and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between the H24 peak values of serum level for ST2 and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days..
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between the H24 peak values of serum level for polymorphonuclear neutrophil and functional and anatomical parameters
Time Frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
|
area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL16_0130
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
Clinical Trials on MRI at D7
-
Assistance Publique - Hôpitaux de ParisRecruitingSARS-CoV2 InfectionFrance
-
Nottingham University Hospitals NHS TrustRecruitingDementia (Diagnosis)United Kingdom
-
Balgrist University HospitalTerminatedAssessment Micro-anatomy of the Menisci and Cartilage After Isolated Acute ACL Injury With MRI at 7TCartilage Injury | ACL Injury | Meniscus LesionSwitzerland
-
CSEM Centre Suisse d'Electronique et de Microtechnique...Institute for Diagnostic and Interventional Neuroradiology, InselspitalRecruitingEpilepsy | Healthy | Psychosis | Essential TremorSwitzerland
-
University of AarhusAarhus University Hospital SkejbyCompletedBundle-Branch Block | Heart Septal Defects, VentricularDenmark
-
University Hospital, BordeauxUnknown
-
University Hospital, Clermont-FerrandRecruiting
-
Nottingham University Hospitals NHS TrustRecruitingMild Cognitive Impairment | Prodromal Alzheimer's DiseaseUnited Kingdom
-
Turku University HospitalOulu University Hospital; Kuopio University Hospital; Seinajoki Central Hospital and other collaboratorsNot yet recruitingAppendicitis | Appendix Cancer | Appendix Mass | Appendix Abscess | Appendix Nec | Appendix Tumor | Appendix Diseases
-
Centre Hospitalier Universitaire, AmiensUnknown